HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation.

AbstractAIMS:
It is presently unknown whether patients with atrial fibrillation (AF) are at increased risk of thrombo-embolic adverse events after interruption of warfarin treatment. The purpose of this study was to assess the risk and timing of thrombo-embolism after warfarin treatment interruption.
METHODS AND RESULTS:
A retrospective, nationwide cohort study of all patients in Denmark treated with warfarin after a first hospitalization with AF in the period 1997-2008. Incidence rate ratios (IRRs) of thrombo-embolic events and all-cause mortality were calculated using the Poisson regression analyses. In total, 48 989 AF patients receiving warfarin treatment were included. Of these, 35 396 patients had at least one episode of warfarin treatment interruption. In all, 8255 deaths or thrombo-embolic events occurred during treatment interruption showing an initial clustering of events with 2717, 835, 500, and 427 events occurring during 0-90, 91-180, 181-270, and 271-360 days after treatment interruption, respectively. Correspondingly, the crude incidence rates were 31.6, 17.7, 12.3, and 11.4 events per 100 patient-years. In a multivariable analysis, the first 90-day interval of treatment interruption was associated with a markedly higher risk of death or thrombo-embolism (IRR 2.5; 95% confidence interval 2.3-2.8) vs. the interval of 271-360 days.
CONCLUSION:
In patients with AF, an interruption of warfarin treatment is associated with a significantly increased short-term risk of death or thrombo-embolic events within the first 90 days of treatment interruption.
AuthorsJakob Raunsø, Christian Selmer, Jonas Bjerring Olesen, Mette Gitz Charlot, Anne-Marie S Olsen, Ditte-Marie Bretler, Jørn Dalsgaard Nielsen, Helena Dominguez, Niels Gadsbøll, Lars Køber, Gunnar H Gislason, Christian Torp-Pedersen, Morten Lock Hansen
JournalEuropean heart journal (Eur Heart J) Vol. 33 Issue 15 Pg. 1886-92 (Aug 2012) ISSN: 1522-9645 [Electronic] England
PMID22199117 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Warfarin
Topics
  • Aged
  • Aged, 80 and over
  • Anticoagulants (therapeutic use)
  • Atrial Fibrillation (complications, drug therapy, mortality)
  • Cause of Death
  • Denmark (epidemiology)
  • Female
  • Hospitalization (statistics & numerical data)
  • Humans
  • Male
  • Retrospective Studies
  • Risk Factors
  • Thromboembolism (etiology, mortality)
  • Warfarin (therapeutic use)
  • Withholding Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: